Jeil Pharmaceutical Co.,Ltd (271980.KS) Stock

271980.KS logo

Jeil Pharmaceutical Co.,Ltd

271980.KSSouth Korea
Healthcare

Company profile

Jeil Pharmaceutical reported revenue of 567.24 billion KRW for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 130.30 billion KRW, down 20.1% from a year before. Its largest business segment, Pharmaceutical Business Division, brought in 99% of segment revenue in fiscal year 2024; South Korea was the largest region with 94%. In Q1 2026 it reported a net loss of 309.81 million KRW, against net income of 2.62 billion KRW a year earlier. Our analysis of its filings shows revenue shrinking from 726.39 billion KRW in fiscal year 2023 to 567.24 billion KRW in fiscal year 2025, 11.6% a year on average. Jeil Pharmaceutical reports about 1,024 full-time employees.

What stands out

  • Revenue fell 19.5% in fiscal year 2025, from 704.54 billion KRW in fiscal year 2024, after a fall of 3.0% the year before.
  • It returned to a profit in fiscal year 2025, 23.38 billion KRW, after a net loss of 29.97 billion KRW in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Jeil Pharmaceutical Co.,Ltd

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Jeil Pharma Holdings Inc49.24%
  • Eung-soo Han6.321 %6.32%
  • Seung-Soo Han3 %3.00%
  • Joo-hye Lee2.403 %2.40%
  • Sang-Cheol Han0.6136 %0.61%

Share of the company, as of September 25, 2026

How much revenue does Jeil Pharmaceutical make?

Jeil Pharmaceutical reported 567.24 billion KRW in revenue for fiscal year 2025, down 19.5% from 704.54 billion KRW in fiscal year 2024. In Q1 2026 revenue was 130.30 billion KRW.

What is Jeil Pharmaceutical's largest business segment?

Pharmaceutical Business Division, with 695.54 billion KRW or 99% of segment revenue in fiscal year 2024. Next: Research & Developent Division (1%).

Where does Jeil Pharmaceutical make most of its revenue?

South Korea: 94% of revenue by region in fiscal year 2024, followed by Overseas (6%).

What companies are similar to Jeil Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ilsung Is Co., Ltd. (003120.KS), Dongwha Pharm.Co.,Ltd (000020.KS), Hana Pharm Co., Ltd. (293480.KS), Ilyang Pharmaceutical Co.,Ltd (007570.KS).

How has Jeil Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 700.69 billion KRW; FY2022, 722.23 billion KRW; FY2023, 726.39 billion KRW; FY2024, 704.54 billion KRW; FY2025, 567.24 billion KRW.

Has Jeil Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 12.47 billion KRW; FY2022, a loss of 13.09 billion KRW; FY2023, 5.00 billion KRW; FY2024, a loss of 29.97 billion KRW; FY2025, 23.38 billion KRW. It reported a net loss in 3 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,024
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
343, Sapyeong-daero, Seoul, 06543
Phone
82 2 549 7451
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Jeil Pharmaceutical Co.,Ltd (271980.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/271980.KS

LinkedInLinkedInXXYouTubeYouTube